These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10882697)

  • 1. In vitro activity of DU-6681a, an active form of the new oral carbapenem compound DZ-2640, in comparison with that of R-95867, faropenem and oral cephalosporins.
    Okuda J; Otsuki M; Oh T; Nishino T
    J Antimicrob Chemother; 2000 Jul; 46(1):101-8. PubMed ID: 10882697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial activity of DU-6681a, a parent compound of novel oral carbapenem DZ-2640.
    Tanaka M; Hohmura M; Nishi T; Sato K; Hayakawa I
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1260-8. PubMed ID: 9174181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Investigation of the antibacterial activity of faropenem against Streptococcus pneumoniae].
    Hanaki H; Inaba Y; Hiramatsu K
    Jpn J Antibiot; 1999 Sep; 52(9):563-70. PubMed ID: 10746191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro bactericidal activities of new oral penem, faropenem against the various clinical isolates].
    Matsuzaki K; Nishiyama T; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J
    Jpn J Antibiot; 1999 May; 52(5):431-8. PubMed ID: 10480050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro activity of faropenem against beta-lactamase producing clinical isolates].
    Nishiyama T; Matsuzaki K; Koyama H; Saika T; Hasegawa M; Kobayashi I
    Jpn J Antibiot; 2000 Mar; 53(3):179-83. PubMed ID: 10834149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target affinities of faropenem to and its impact on the morphology of gram-positive and gram-negative bacteria.
    Dalhoff A; Nasu T; Okamoto K
    Chemotherapy; 2003 Jul; 49(4):172-83. PubMed ID: 12886052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The in-vitro activity of faropenem, a novel oral penem.
    Woodcock JM; Andrews JM; Brenwald NP; Ashby JP; Wise R
    J Antimicrob Chemother; 1997 Jan; 39(1):35-43. PubMed ID: 9044026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro and in-vivo antibacterial activities of CS-834, a new oral carbapenem.
    Sakagawa E; Otsuki M; Oh T; Nishino T
    J Antimicrob Chemother; 1998 Oct; 42(4):427-37. PubMed ID: 9818740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR; Frei CR; Burgess DS
    Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro evaluation of faropenem activity against anaerobic bacteria.
    Behra-Miellet J; Dubreuil L; Bryskier A
    J Chemother; 2005 Feb; 17(1):36-45. PubMed ID: 15828442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro activity of meropenem imipenem, the penem HRE 664 and ceftazidine against clinical isolates from West Germany.
    Bauernfeind A; Jungwirth R; Schweighart S
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():73-84. PubMed ID: 2509418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro susceptibility testing of 446 clinical isolates of gram-positive bacteria to new quinolones, carbapenems and cephalosporins].
    Cereda RF; Pignatari AC; Leme IL; Jones RN; Sader HS
    Rev Assoc Med Bras (1992); 1996; 42(3):130-4. PubMed ID: 9138353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gram-negative bacilli resistant to third-generation cephalosporins: beta-lactamase characterization and susceptibility to Sch 34343.
    Medeiros AA; Hare R; Papa E; Adam C; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():119-32. PubMed ID: 3875602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
    Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
    J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In vitro antibacterial activity of faropenem, a novel oral penem antibiotic, against enterohemorrhagic Escherichia coli O157 strains].
    Nasu T; Okamoto K; Nakanishi T; Nishino T
    Jpn J Antibiot; 1999 Aug; 52(8):541-53. PubMed ID: 10587879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro activity of S-4661, a new parenteral carbapenem, and other antimicrobial agents against respiratory pathogens.
    Watanabe A; Takahashi H; Kikuchi T; Kobayashi T; Gomi K; Fujimura S; Tokue Y; Nukiwa T
    Chemotherapy; 2000; 46(3):184-7. PubMed ID: 10765033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Faropenem, a new oral penem: antibacterial activity against selected anaerobic and fastidious periodontal isolates.
    Milazzo I; Blandino G; Caccamo F; Musumeci R; Nicoletti G; Speciale A
    J Antimicrob Chemother; 2003 Mar; 51(3):721-5. PubMed ID: 12615878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of faropenem and imipenem for ciprofloxacin-resistant bacteria.
    Piddock LJ; Johnson MM; Webber MA
    J Antimicrob Chemother; 2003 Sep; 52(3):500-2. PubMed ID: 12917244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-lactamase stability of faropenem.
    Dalhoff A; Nasu T; Okamoto K
    Chemotherapy; 2003 Sep; 49(5):229-36. PubMed ID: 14504433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Penicillin-binding proteins and beta-lactamases: their effects on the use of cephalosporins and other new beta-lactams.
    Neu HC
    Curr Clin Top Infect Dis; 1987; 8():37-61. PubMed ID: 3077281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.